Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease

Physiological Research

Volumn 53, Issue 5, 2004, Pages 481-486

  Frohlich, J ^a   Dobiášová, Milada ^b   Adler, L ^a   Francis, M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Coronary angiography; Coronary artery disease; Gender; Immunoradiometric assay; Lipoprotein(a)

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENDER; HUMAN; IMMUNORADIOMETRIC ASSAY; LIPOPROTEIN BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

AGE DISTRIBUTION; BIOLOGICAL MARKERS; BRITISH COLUMBIA; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; SMOKING;

EID: 8444220516     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BDEIR K, CANE W, CANZIANI G, CHAIKENI, WEISEL J, KOSCHINSKY ML, LAWN RM, BANNERMAN PG, SACHAIS BS, KUO A, HANCOCK MA, TOMASZEWSKI J, RAGHUNATH PN, GANZ T, HIGAZI AA, CINES DB: Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 94: 2007-2019, 1999.
2. BOSTOM, GAGNON DR, CUPPLES, WILSON PW, JENNER JL, ORDOVAS JM, SCHAFER EJ, CASTELLI A: Prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 90: 1688-1695, 1994.
3. BOWDEN JF, PRITCHARD PH, HILL JS, FROHLICH JJ: Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. Arterioscler Thromb 14: 1561-1568, 1994.
4. BROWN G, ALBERS JJ, FISHER LD, SCHAEFER SM, LIN JT, KAPLAN C, ZHAO XQ, BISSON BD, FITZPATRICK VF, DODGE HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289-1298, 1990.
5. BUDDE T, FECHTRUP C, BOSENBERG E, VIELHAUER C, ENBERGS A, SCHULTE H, ASSMANN G, BREITHARDT G: Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 14: 1730-1436, 1994.
6. CANTIN B, GAGNON F, MOORJANI S, DESPRES JP, LAMARCHE B, LUPIEN PJ, DAGENAIS GR: Is Lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 31: 519-525,1998.
7. CREMER P, NAGEL D, LABROT B, MANN H, MUCHE R, ELSTER H, SEIDEL D: Lipoprotein(a) as predictor of myocardial infarction in comparison with fibrinogen, LDL cholesterol and other risk factors: results from prospective Gottingen Risk Incidence and Prevalence Study. Eur J Clin Invest 24: 444-453, 1994.
8. DAHLEN GH, GUYTON JR, ATTAR M, FARMER JA, KAUTZ JA, GOTTO AM Jr: Association of levels of lipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease, documented by angiography. Circulation 74: 758-765, 1986.
9. DANGAS G, AMBROSE JA, D'AGATE DJ: Correlation of plasma lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. Am J Cardiol 83: 583-585, 1999.
10. HDL). Clin Biochem 34: 583-588, 2001.
11. GANNE F, VASSE M, BEAUDEUX JL, PEYNET J, FRANCOIS A, PAYSANT J, LENORMAND B, COLLET JP, VANNIER JP, SORIA J, SORIA C: Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins: consequences for plasmin generation and monocyte adhesion. Thromb Haemost 81: 594-600, 1999.
12. GAZZARUSSO C, GARZANITI A, BUSCAGLIA P, BONETTI G, FALCONE C, FRATINO P, FINARDI G, GEROLDI D: Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of lipoprotein(a) polymorphism. J Cardiovasc Risk 5: 37-42, 1998.
13. GUYTON JR, DAHLEN GH, PATSCH W, KAUTZ JA, GOTTO AM Jr: Relationship of plasma lipoprotein(a) levels to race and to apoprotein B. Arteriosclerosis 5: 265-272, 1985.
14. LUNDSTAM U, HURT-CAMEJO E, OLSSON G, SARTIPY P, CAMEJO G, WIKLUND O: Proteoglycans contribution on association of Lp(a) and LDL with smooth muscle cell extracellular matrix. Arterioscler Thromb Vasc Biol 19: 1162-1167, 1999.
15. MARCOVINA SA, KOSCHINSKY ML: Lipoprotein(a): Structure, measurement, and clinical significance. In Handbook of Lipoprotein Testing, RIFAI N, WARNICK RG, DOMINICZAK MH (eds), AACC Press, Washington, DC, 2000, pp 345-386.
16. MARCOVINA SM, ALBERS JJ, WIJSMAN E, ZHANG Z-H, CHAPMAN NH, KENNEDY H: Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. J Lipid Res 37: 2569-2585, 1996.
17. MORRISETT JD: The role of lipoprotein(a) in atherosclerosis. Curr Atheroscler Rep 2: 243-250, 2000.
18. NGUYEN TT, ELLEFSON RD, HODGE DO, BAILEY KR, KOTTKE TE, ABU-LEBDEH HS: Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 96: 1390-1397, 1997.
19. ORTH-GOMER K, MITTLEMAN MA, SCHENCK-GUSTAFSSON K, WAMALA SP, ERIKSSON M, BELKIE K, KIRKEEIDE R, SVANE B, RYDEN L: Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 95: 329-334, 1997.
20. PAULTRE F, PEARSON TA, WEIL HF, TUCK CH, MYERSON M, RUBIN J, FRANCIS CK, MARX HF, PHILBIN EF, REED RG, BERGLUND L: High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 20: 2619-2624, 2000.
21. SALOMAA V, RASI V, PEKKANEN J, VAHTERA E, JAUHIAINEN M, VARTIAINEN E, MYLLYLA G, EHNHOLM C: Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. Eur Heart J 15: 1293-1299, 1994.
22. SMITH SC, GREENLAND P, GRUNDY SM: Prevention conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention. Executive summary. Circulation 101: 111-116, 2000.
23. SOULAT T, LOYAU S, BAUDOUIN V, DURLACH V, GILLERY P, GARNOTEL R, LOIRAT C, ANGLES CANO E: Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin: a study with individual plasmas presenting natural variations of Lp(a). Thromb Haemost 82: 121-127, 1999.
24. WEBER M, MCNICOLL S, MARCIL M, CONNELLY P, LUSSIER-CACAN S, DAVIGNON J, LATOUR Y, GENEST J Jr: Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature artery disease in French Canadians. Can J Cardiol 13: 253-260, 1997.
25. WILSON SH, CELERMAJER DS, NAKAGOMI A, WYNDHAM RN, JANU MR, BEN FREEDMAN S: Vascular risk factors correlate to the extent as well as the severity of coronary atherosclerosis. Coron Artery Dis 10: 449-453, 1999.